Merus

Merus NV is a clinical-stage immuno-oncology company, which engages in the discovery and development of bispecific antibody therapeutics. Its pipeline includes Biclonics for solid and hematological tumors. The company was founded by Ton Logtenberg and Hennie Hoogenboom on June 16, 2003 and is headquartered in Utrecht, the Netherlands.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

UTRECHT, The Netherlands and CAMBRIDGE, Mass., July 28, 2023 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (Merus, the Company, we, or our), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics® and Triclonics®), today announced two abstracts were selected for presentation at the European Society for Medical Oncology Congress (ESMO) 2023.

Merus Announces Two Clinical Abstracts on Zenocutuzumab (Zeno) in NRG1-fusion (NRG1+) non-small cell lung cancer (NSCLC) and Pancreatic Cancer (PDAC) Selected for Presentation at the ESMO Congress 2023

– Zeno granted BTD for the treatment of NRG1+ non-small cell lung cancer UTRECHT, The Netherlands and CAMBRIDGE, Mass., July 05, 2023 (GLOBE NEWSWIRE) -- Merus N.V.

Zenocutuzumab (Zeno) granted second Breakthrough Therapy Designation by the U.S. Food & Drug Administration

Shares of Merus NV MRUS, +3.02% rallied as much as 10% in the extended session Thursday after the pharma company said the U.S. Food and Drug Administration has granted one of its cancer treatments a breakthrough therapy designation, intended for expedite the development and review of a drug to treat serious illness. The drug, zenocutuzumab, is geared to the treatment of patients with a type of advanced, metastatic pancreatic cancer.

Merus stock jumps 10% after FDA's action on cancer drug

UTRECHT, The Netherlands and CAMBRIDGE, Mass., June 29, 2023 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics® and Triclonics®) for cancer, today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation (BTD) for zenocutuzumab (Zeno) for the treatment of patients with advanced unresectable or metastatic NRG1 fusion (NRG1+) pancreatic cancer following progression with prior systemic therapy or who have no satisfactory alternative treatment options. This designation for Zeno follows a Fast Track Designation for the treatment of patients with metastatic solid tumors harboring NRG1 gene fusions (NRG1+ cancer) that have progressed on standard of care therapy on January 7, 2021 and Orphan Drug Designation for the treatment of patients with pancreatic cancer on July 27, 2020.

Zenocutuzumab (Zeno) granted Breakthrough Therapy Designation by the U.S. Food & Drug Administration for the treatment of NRG1+ pancreatic cancer

UTRECHT, The Netherlands and CAMBRIDGE, Mass., June 15, 2023 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics® and Triclonics®), today announced the appointment of Greg Perry as the Company's Chief Financial Officer (CFO). Additionally, Greg has been designated as the Company's principal financial officer, succeeding Bill Lundberg, M.D., in such role. In connection with his appointment as the Company's Chief Financial Officer, on June 14, 2023, Greg resigned from the Company's Board of Directors.

Merus Appoints Life Sciences Strategic and Financial Industry Veteran Greg Perry as Chief Financial Officer

Darling Ingredients

Tenet Healthcare

Viking Therapeutics

Chemed

Lantheus Holdings

Carrols Restaurant Group

Stock screeners can help investors identify stocks to buy based on a variety of criteria. In fact, one helpful predictor of stock price growth can be found with analyst ratings.

7 Stocks That Wall Street Analysts Are Loving in May

Does Merus N.V. (MRUS) have what it takes to be a top stock pick for momentum investors?

Here's Why Merus N.V. (MRUS) is a Great Momentum Stock to Buy

The consensus price target hints at an 114.6% upside potential for Merus N.V. (MRUS). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Wall Street Analysts Believe Merus N.V. (MRUS) Could Rally 114.58%: Here's is How to Trade

Merus N.V. (MRUS) came out with a quarterly loss of $0.86 per share versus the Zacks Consensus Estimate of a loss of $1.07. This compares to loss of $0.43 per share a year ago.

Merus N.V. (MRUS) Reports Q1 Loss, Tops Revenue Estimates

– Petosemtamab clinical update presented at the American Association of Cancer Research (AACR) Annual Meeting 2023 – Petosemtamab end-of-phase meeting with U.S. Food & Drug Administration provides clarity to potential registration path in head and neck squamous cell carcinoma (HNSCC) – Petosemtamab update planned for Q3 2023 on potential registrational path in HNSCC – Based on the Company's current operating plan, existing cash, cash equivalents and marketable securities expected to fund Merus' operations into second half 2025

Merus Announces Financial Results for the First Quarter 2023 and Provides Business Update

Merus N.V. (MRUS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Analysts Estimate Merus N.V. (MRUS) to Report a Decline in Earnings: What to Look Out for

- 37% overall response rate (ORR) observed in 43 evaluable patients- 6 months median duration of response as of Feb. 1, 2023 data cutoff date- End-of-phase meeting with U.S. Food & Drug Administration provides clarity to potential registration path in HNSCC- Investor call on April 17, 2023 at 6:30 p.m. ET

Merus' Petosemtamab Interim Data Demonstrates Clinically Meaningful Activity in Previously Treated Head and Neck Squamous Cell Carcinoma (HNSCC)

- Robust 36% overall response rate (ORR) in 42 evaluable patients - 6 months median duration of response with 17 patients still on treatment as of Nov. 28, 2022 data cutoff - End-of-Phase meeting with U.S. Food & Drug Administration provides clarity to potential registration path in HNSCC - Investor call on April 17, 2023 at 6:30 p.m. ET ET UTRECHT, The Netherlands and CAMBRIDGE, Mass.

Merus Announces Publication of an Abstract on Petosemtamab Monotherapy in Previously Treated Head and Neck Squamous Cell Carcinoma for Plenary Session Oral Presentation at the AACR Annual Meeting 2023 and Provides a Program and Regulatory Update

UTRECHT, The Netherlands and CAMBRIDGE, Mass., April 14, 2023 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (Merus, the Company, we, or our), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics® and Triclonics®), today announced the publication of an abstract for a poster presentation of early clinical data on the bispecific antibody petosemtamab in advanced gastric/esophageal adenocarcinoma (GEA) at the American Association for Cancer Research (AACR) Annual Meeting 2023 taking place in Orlando, Florida April 14-19, 2023.

Merus Announces Publication of an Abstract on Petosemtamab in Advanced Gastric/Esophageal Adenocarcinoma for Presentation at the AACR Annual Meeting 2023

Merus N.V. develops bispecific and trispecific antibodies for cancer. They have deals with an array of big pharma.

Merus: Dutch Drug Developer With An Interesting Platform

Poster presentation: Tuesday, April 18, 2023, 1:30-5:30 p.m. ET Poster presentation: Tuesday, April 18, 2023, 1:30-5:30 p.m. ET

Merus Announces Publication of an Abstract on Preclinical Mechanism of Action of MCLA-129 Selected for Poster Presentation at the AACR Annual Meeting 2023

– Plenary session oral presentation: Monday, April 17, 2023, 10:15 a.m.-12:15 p.m. ET– Poster presentation on petosemtamab in advanced gastric/esophageal adenocarcinoma: Monday, April 17, 2023, 1:30-5:30 p.m. ET– Investor call on Monday, April 17, 2023 at 6:30 p.m. ET

Merus Announces Petosemtamab in Previously Treated Head and Neck Squamous Cell Carcinoma Abstract Selected for Plenary Session Oral Presentation at the AACR Annual Meeting 2023

– Zenocutuzumab (Zeno) in NRG1+ cancer potential registrational path and timeline update planned for first half of 2023

Merus Announces Financial Results for the Fourth Quarter and Full Year 2022 and Provides Business Update

Merus (MRUS) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Is a Surprise Coming for Merus (MRUS) This Earnings Season?

Merus N.V. (MRUS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Merus N.V. (MRUS) Expected to Beat Earnings Estimates: Should You Buy?

Merus N.V. (MRUS) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

Strength Seen in Merus N.V. (MRUS): Can Its 12.6% Jump Turn into More Strength?

In a release issued January 8, 2023 by Merus N.V. (Nasdaq:MRUS) with the same headline, an error was made stating Merus plans to provide a regulatory path and program update on petosemtamab in the second half of 2023, which has been corrected to indicate this update is planned for the first half of 2023. Further, an error was made stating Merus has initiated a cohort evaluating Zeno in monotherapy in castration resistant prostate cancer, this has been corrected to indicate this is not in monotherapy, but in addition to Enzalutamide or Abiraterone acetate. The corrected release further discloses that Merus plans to provide an update on the potential registrational path and timeline of Zeno in NRG1+ cancer in the first half of 2023. The corrected release follows:

CORRECTING and REPLACING --Merus Provides 2023 Outlook

- As of year-end 2022, more than 150 patients with NRG1 gene fusion positive (“NRG1+”) cancer have been treated with zenocutuzumab (“Zeno”) monotherapy

Merus Provides 2023 Outlook

Merus N.V. (MRUS) delivered earnings and revenue surprises of 11.67% and 38.84%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Merus N.V. (MRUS) Reports Q3 Loss, Misses Revenue Estimates

– Clinical update of MCLA-129 presented at the 34th EORTC/NCI/AACR (ENA) Symposium on Molecular Targets and Cancer Therapeutics – Zenocutuzumab (Zeno) Regulatory update: FDA recommends additional enrollment in eNRGy trial to support potential BLA filing – Clinical update of petosemtamab planned for first half of 2023

News for Merus Stock (MRUS)